Mendelsohn shares Tang Prize for leadership in developing targeted therapy
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to block cancer-promoting growth factor receptors on the surface of cancer cells.
In announcing the award on June 19 in Taiwan, the Tang Foundation noted the three awardees launched the...
MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and TRACTION...
Checkpoint inhibitor shrinks advanced squamous cell skin cancer
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of...